A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).

Trial Details

NCT ID

NCT06646276

Phase

PHASE3

Sponsor

Bristol-Myers Squibb

Status

RECRUITING

Cancer Type

Small Cell (SCLC) Lung Cancer

Interventions

• BMS-986489 (BMS-986012+Nivolumab)
• Atezolizumab
• Carboplatin
• Etoposide

Locations (sample)

• Daphne, Alabama, United States|30.60353,-87.9036
• Hot Springs, Arkansas, United States|34.5037,-93.05518
• Fort Myers, Florida, United States|26.62168,-81.84059
• Orange City, Florida, United States|28.94888,-81.29867
• St. Petersburg, Florida, United States|27.77086,-82.67927

Key Eligibility Criteria

• Participants must have diagnosis of Extensive-Stage Small Cell Lung Cancer (ES-SCLC).
• Participants must be Healthy enough to do their normal activities with little or no help based on the ECOG performance scale.
• Participants must have at least one tumor that can be measured using special imaging techniques like a CT scan or MRI at a site other than the brai…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.